TV 1380

Drug Profile

TV 1380

Alternative Names: Albu-CocH; AlbuBChE; Cocaine hydrolase - Teva; Recombinant human serum albumin mutated butyrylcholinesterase; TV-1380

Latest Information Update: 21 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoGenesys
  • Developer Teva Pharmaceutical Industries
  • Class Antidotes; Cholinesterases; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cocaine abuse

Most Recent Events

  • 21 Mar 2016 No recent reports on development identified - Phase-II for Cocaine abuse in Spain and USA (IM)
  • 01 Oct 2014 Teva Pharmaceutical completes a phase II trial in Cocaine abuse in USA and Spain (NCT01887366)
  • 17 Sep 2013 Phase-II clinical trials in Cocaine abuse in Spain (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top